Summary of Key Points Core Viewpoint - The company has completed the repurchase and cancellation of 3,844,966 restricted shares, which accounts for approximately 0.63% of the total share capital prior to the repurchase, as part of its 2024 restricted stock incentive plan [1][4][7]. Group 1: 2024 Restricted Stock Incentive Plan - The company has proposed a 2024 restricted stock incentive plan, which includes a draft and management measures for implementation [1][2]. - The plan was approved by the shareholders, allowing the board to determine the grant date and manage all necessary matters related to the stock grants [2][3]. - The initial number of recipients for the stock grants was adjusted from 119 to 117, with the total number of restricted shares remaining unchanged [3]. Group 2: Repurchase and Cancellation of Restricted Shares - The company has terminated the implementation of the 2024 restricted stock incentive plan and repurchased all unvested restricted shares, totaling 3,844,966 shares [4][6]. - The repurchase price for the restricted shares was set at 6.372 yuan per share, with a total expenditure of 24,941,489.25 yuan sourced from the company's own funds [6]. Group 3: Changes in Share Capital Structure - Following the repurchase, the total number of shares will decrease from 612,469,590 to 608,624,624 [4][5]. - The structure of the share capital will reflect a reduction in restricted shares, while the overall distribution of shares will remain compliant with listing requirements [4][7]. Group 4: Impact on Company Operations - The repurchase and cancellation of restricted shares are not expected to materially affect the company's financial status or operational results [7].
迈克生物: 关于限制性股票回购注销完成的公告